Last 307.25 GBp
Change Today +0.25 / 0.08%
Volume 14.7K
SKP On Other Exchanges
Symbol
Exchange
London
OTC US
OTC US
Frankfurt
As of 6:56 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

skyepharma plc (SKP) Snapshot

Open
295.00 GBp
Previous Close
307.00 GBp
Day High
307.25 GBp
Day Low
295.00 GBp
52 Week High
12/1/14 - 377.50 GBp
52 Week Low
03/25/14 - 159.34 GBp
Market Cap
322.0M
Average Volume 10 Days
134.4K
EPS TTM
-0.22 GBp
Shares Outstanding
104.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SKYEPHARMA PLC (SKP)

Related News

No related news articles were found.

skyepharma plc (SKP) Related Businessweek News

No Related Businessweek News Found

skyepharma plc (SKP) Details

Skyepharma PLC develops oral and inhalation pharmaceutical products. The company’s products include flutiform, a unique inhaled combination product which has been approved in 31 countries; and Pacira’s Exparel, an amide local anesthetic indicated for single-dose infiltration into the surgical site to produce extended postsurgical analgesia. Skyepharma’s inhalation technology has been licensed to GlaxoSmithKline for use in Breo/Relvar, Anoro, and Incruse. Skyepharma is also developing a novel inhaled therapy, SKP-2075, as a potential anti-inflammatory treatment for COPD. Skyepharma’s oral technologies are used in 10 products marketed by various companies in approximately 80 countries. The company has partnerships with various companies, including GlaxoSmithKline, Sanofi, Mundipharma, and Kyorin worldwide. Skyepharma PLC was founded in 1910 and is headquartered in London, the United Kingdom.

79 Employees
Last Reported Date: 03/28/14
Founded in 1910

skyepharma plc (SKP) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 567.0K GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 74.0K GBP
Compensation as of Fiscal Year 2013.

skyepharma plc (SKP) Key Developments

Skyepharma PLC Announces Early Repayment of the Remainder of the CRC Finance Facility

Skyepharma PLC announced that it has given notice to CRC European Loan Origination Platform Limited (CRC) to repay the entire outstanding U.S. Dollar principal of the CRC Finance facility. This follows the early repayment of the outstanding Euro principal in October 2014 and will result in the facility being fully repaid and terminated. The outstanding USD principal of $15.1 million (£9.9 million at current rates) will be repaid on 27 February 2015 at a cost of £10.5 million (at current rates) including accrued interest and a make-whole amount of 4.4%. The early settlement of the remainder of the facility will result in a total saving for the group of £0.9 million (net of the make-whole amount) compared with the amounts which would otherwise be payable based on current interest rates through to the normal maturity date of 31 December 2016.

Skyepharma PLC Launches the 120-Puff Treatment Version of Flutiform® in Japan

Skyepharma PLC announced that the 120-puff treatment version in strengths of 50/5µg and 125/5µg for a 30-day supply of flutiform® has been launched in Japan by its licensing partner, Kyorin Pharmaceutical Co Ltd. Under its agreement with Kyorin, Skyepharma is responsible for arranging the manufacture and supply of flutiform®.

Skyepharma PLC Launches flutiform® in Spain and in Italy as Abriff®

Skyepharma PLC announced that the regulatory approval and agreement on pricing reimbursement, flutiform® has now been launched in Spain for the treatment of bronchial asthma. It has also been launched in Italy as Abriff® under a co-marketing agreement. flutiform® and Abriff® combine the fast-acting long-acting beta agonist (LABA) formoterol with the most widely prescribed inhaled corticosteroid (ICS) fluticasone. In Italy, Abriff® has been launched by Mundipharma's co-marketing partner, Zambon Italia srl.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SKP:LN 307.25 GBp +0.25

SKP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abzena PLC 82.25 GBp +0.25
BioDelivery Sciences International Inc $14.89 USD -0.09
Flamel Technologies SA $16.02 USD -0.13
Onxeo €6.31 EUR -0.11
Vectura Group PLC 148.00 GBp -3.50
View Industry Companies
 

Industry Analysis

SKP

Industry Average

Valuation SKP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.7x
Price/Book 7.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SKYEPHARMA PLC, please visit www.skyepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.